Back to top

Piper Sandler Remains a Buy on Context Therapeutics (CNTX)

Piper Sandler analyst Biren Amin reiterated a Buy rating on Context Therapeutics (CNTX – Research Report) on June 26 and set a price target of $4.0...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Context Therapeutics Inc. (CNTX)